ADVENTRX Pharmaceuticals Inc (Anx) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ADVENTRX Pharmaceuticals Inc (Anx)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: estatemakr who wrote (170)	6/14/2007 5:38:39 PM
From: Keith Feral	Read Replies (2) of 418

Fact - US phase 2 began dosing on May 4, 2005 and announced positive results on March 7, 2005. We all know the results exceeded Adventrx's expected response rate of 25%. Bottom line, it only took 11 months to complete the entire study from start to finish. They announced some results as early as Jan 25, 2005. It only took 9 months to produce results from the inception of the trial. Fact - European Phase 2 b trials began on May 31, 2005 and enrollment was completed on Sept 25, 2006. As of June 14, 2007 there are patients still on protocol. The last patients have been on protocol for 9 months now. To me, it's quite obvious these trials are going much better for Adventrx, measured by the length of time the patients have been on trial. I can only assume that the successful treatment of these patients into the 9th month of monotherapy is a great thing for Cofactor. We all need to start thinking about how good it is to wait for the data. The longer we wait, the better the ttp, response rate and other preliminary data including the toxicity results. We can only assume it's a win win for efficacy and toxicity at this point.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next